In yesterday’s Wall Street session, Unity Biotechnology Inc. (NASDAQ:UBX) shares traded at $4.56, up 5.80% from the previous session.
As of this writing, 5 analysts cover Unity Biotechnology Inc. (NASDAQ:UBX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $120.00 and a low of $12.00, we find $35.00. Given the previous closing price of $4.31, this indicates a potential upside of 712.06 percent. UBX stock price is now 55.85% away from the 50-day moving average and -19.09% away from the 200-day moving average. The market capitalization of the company currently stands at $61.38M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
There are 0 analysts who have given it a hold rating, whereas 5 have given it a buy rating. Brokers who have rated the stock have averaged $56.40 as their price target over the next twelve months.
On November 10, 2021, Mizuho Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock increasing its target price from $5 to quote $7, while ‘Citigroup’ rates the stock as ‘Buy’.
In other news, Ghosh Anirvan, Chief Executive Officer sold 1,274 shares of the company’s stock on Dec 14. The stock was sold for $3,631 at an average price of $2.85. Upon completion of the transaction, the Chief Executive Officer now directly owns 95,948 shares in the company, valued at $0.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 14, Chief Medical Officer Dananberg Jamie sold 1,016 shares of the business’s stock. A total of $2,896 was realized by selling the stock at an average price of $2.85. This leaves the insider owning 65,105 shares of the company worth $0.3 million. Insiders disposed of 128,163 shares of company stock worth roughly $0.58 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in UBX stock. A new stake in Unity Biotechnology Inc. shares was purchased by ARCH VENTURE MANAGEMENT, LLC during the first quarter worth $45,820,000. ALYESKA INVESTMENT GROUP, L.P. invested $5,864,000 in shares of UBX during the first quarter. In the first quarter, EMPERY ASSET MANAGEMENT, LP acquired a new stake in Unity Biotechnology Inc. valued at approximately $2,012,000. ALTIUM CAPITAL MANAGEMENT LP acquired a new stake in UBX for approximately $1,947,000. ADAGE CAPITAL PARTNERS GP, L.L.C. purchased a new stake in UBX valued at around $1,596,000 in the second quarter. In total, there are 77 active investors with 46.10% ownership of the company’s stock.
Monday morning saw Unity Biotechnology Inc. (NASDAQ: UBX) opened at $4.3900. During the past 12 months, Unity Biotechnology Inc. has had a low of $2.09 and a high of $18.50. As of last week, the company has a debt-to-equity ratio of 0.26, a current ratio of 6.10, and a quick ratio of 6.10. The fifty day moving average price for UBX is $2.9259 and a two-hundred day moving average price translates $5.6360 for the stock.
The latest earnings results from Unity Biotechnology Inc. (NASDAQ: UBX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$1.9, beating analysts’ expectations of -$2.8 by 0.9. This compares to -$2.97 EPS in the same period last year.
Unity Biotechnology Inc.(UBX) Company Profile
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
